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A B S T R A C TWe performed a cost-effectiveness study of different strategies of
screening for cardiotoxicity in patients receiving imatinib, the first
strategy based on yearly echocardiograms in all patients and the
second strategy based on yearly B-type natriuretic peptide level
measurement, reserving echocardiograms for patients with an abnor-
mal test result. Results are presented in terms of additional cost per
diagnosis as compared with not performing any screening. From the
Brazilian private sector’s perspective, strategies 1 and 2 resulted in
additional costs of US $30,951.53 and US $19,925.64 per diagnosis of
cardiotoxicity, respectively. From the perspective of the Brazilian
public health system, the same strategies generated additional costs
of US $7,668.00 and US $20,232.87 per diagnosis, respectively. In ournt matter Copyright & 2012, International Society
r Inc.
.1016/j.vhri.2012.09.005
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50 CEP 96030-001, Pelotas, RS, Brazil.study, systematic screening for cardiotoxicity in patients using ima-
tinib has a high cost per diagnosis. If screening is to be adopted, a
strategy based on B-type natriuretic peptide level measurement,
reserving echocardiography for patients with abnormal results,
results in lower costs per diagnosis in the private sector. From the
public health system’s perspective, costs per diagnosis will greatly
depend on the reimbursement values adopted for B-type natriuretic
peptide level measurement.
Keywords: cardiac toxicity, cost-effectiveness, economic analysis,
imatinib, side effects.
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Cardiotoxicity remains the limiting factor for many forms of
chemotherapy, and it is a cause for concern among physicians
and patients due to its potential impact on the overall prognosis
and survival of cancer [1]. Pathological changes in the myo-
cardium do not necessarily translate into clinically significant
cardiac toxicity [2], and distinguishing between symptoms of
heart failure (HF) and chemotherapy-related adverse effects can
be challenging [3]. Consequently, accurate and specific tests,
including cardiac biomarkers, echocardiography, and radionu-
clide ventriculography, are essential for improving early detection
of cardiac injury and dysfunction [2,4].
Screening and prevention strategies have been a growing field
for research. Screening for cardiac dysfunction by using periodic
imaging with two-dimensional echocardiography is a standard
part of the care of patients receiving potentially cardiotoxic
chemotherapy agents, such as anthracyclines and trastuzumab
[5]. This strategy, however, is not established for other potential
cardiotoxic drugs, such as the tyrosine-kinase inhibitors imatinib,
dasatinib, nilotinib, sorafenib, and lapatinib [6].Imatinib is a relatively recent option for the treatment of
chronic myeloid leukemia, and its demonstrated effectiveness
has made it the standard first-line therapy for that condition.
It is also effective in treating gastrointestinal stromal tumors,
Philadelphia chromosome-positive acute lymphoblastic leuke-
mia, myeloproliferative diseases associated with PDGFR gene
arrangements, advanced systemic mastocytosis, hypereosinophi-
lic syndrome, chronic eosinophilic leukemia, and advanced
dermatofibrosarcoma protuberans [7–11]. Therefore, its chronic
use has been growing in the past years.
Regarding imatinib’s potential for cardiotoxicity, initial studies
and animal models showed evidence of potential imatinib-
induced HF [12], but recent studies with larger samples suggest
that the incidence of HF after long-term use of imatinib is much
lower than what is observed with anthracyclines [13–16]. Retro-
spective analysis of a phase III trial including 1276 patients has
shown an incidence rate of imatinib-induced HF of 0.2% per year,
which is similar to the rate expected in an age- and gender-
matched population [15]. Another retrospective study including
285 patients with a median treatment time of 3.0 years has
shown an incidence rate of 1.0% [16]. In a cross-sectional studyfor Pharmacoeconomics and Outcomes Research (ISPOR).
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Fig. 1 – Decision tree representing the evaluated screening strategies. BNP, B-type natriuretic peptide; CML, chronic myeloid
leukemia; echo, echocardiogram.
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90 patients with chronic myeloid leukemia under imatinib therapy
for a median treatment time of 3.3 years, a comprehensive cardiac
evaluation has shown that 2.2% of the patients had signs of
cardiotoxicity [13].
This raises an important question: If HF induced by imatinib is a
rare event, should routine screening be advised? Measurement of
plasma B-type natriuretic peptide (BNP) level has been suggested as a
useful marker for the detection of imatinib-related cardiotoxicity.
Considering the importance of the adverse effect, some authors
recommended a strategy of monitoring all patients by serial BNP
plasma level measurement [17], but the current utility and cost-
effectiveness of this approach are not known. Screening would allow
early detection of myocardial injury, but it could increase costs
significantly, and still result in a greatmajority of negative test results.
On the basis of findings of recent studies on the risk of
imatinib-induced cardiotoxicity [13,14], we performed a cost-
effectiveness study of different screening strategies, based on
two-dimensional echocardiography and BNP levels.Methods
Model Structure
We built a decision tree comparing two different strategies for
cardiotoxicity screening in patients taking imatinib (Fig. 1). The
first strategy was based on performing an echocardiogram once a
year in all patients, while the second strategy used yearly BNP
level measurement as the initial screening test, and only patients
with an abnormal test result had echocardiography.
Input Parameters
To obtain the frequency of abnormal examination results and of
cardiotoxicity, we used data from a cross-sectional study in
which consecutive patients with chronic myeloid leukemia using
imatinib were included, from the outpatient clinic of the Hema-
tology Service of the Federal University of Minas Gerais, Brazil, an
academic tertiary referral center. Exclusion criteria were any kind
of established heart disease (valvular or congenital heart disease,
HF, pacemaker usage, and history suggestive of coronary heartdisease), history of atrial or ventricular arrhythmias, resistant
arterial hypertension (blood pressure above goal in spite of the
concurrent use of three antihypertensive agents of different classes
at optimal dose amounts), significant anemia (hemoglobin level
lower than 9 g/dl), chronic obstructive pulmonary disease (sug-
gested by clinical signs, symptoms, risk factors, and radiologic
alterations or confirmed by spirometry), and history of alcohol or
substance abuse or dependence. Included patients (mean age
48  15 years) were in treatment with imatinib for a median of
3.3 years. Patients were submitted to extensive cardiac screening,
which consisted of an evaluation of the medical history, a physical
examination with special attention to signs and symptoms related
to HF, electrocardiography, echocardiography, and BNP plasma level
measurement. Detailed results have been published previously
[14], and the observed frequency of cardiotoxicity was 1% per year.
We defined cardiotoxicity as a significant decline in left ven-
tricular systolic function, as measured by echocardiography. All
relevant parameters used in the model are described in Table 1.
Costs
In our first analysis, costs for echocardiograms and BNP level
measurements are based on reimbursement values paid by
private health insurance companies in Brazil. In a second
analysis, we used reimbursement values from the public health
system (PHS) for the cost of echocardiography. The Brazilian PHS
does not, at this moment, however, reimburse BNP level mea-
surement; therefore, in the analysis, we assumed the cost of BNP
level measurement in the PHS to be the same as in the private
sector and explored the possibility of a significantly lower value
in the sensitivity analysis. Costs can be found in Table 1.
Because the World Bank’s purchasing power parity conversion
rates for the Brazilian currency (R $) have not been updated in the
last year [20], and significant changes in the Brazilian real and
United States dollar (US $) exchange rate have occurred in that
period, we chose to report all costs in US $, using current official
exchange rates [21], in which R $1.56 ¼ US $ 1.00.
Sensitivity Analyses
The largest available studies evaluating the issue have reported a
similar incidence rate of imatinib cardiotoxicity, between 0.97%
Table 1 – Input data and limits for sensitivity analysis.
Baseline Lower limit Upper limit Reference
Probabilities (%)
Abnormal echocardiogram (per year) 0.33 0.17 0.66 [14]
Abnormal BNP level (per year) 1.33 0.66 2.66 [14]
Abnormal echocardiogram (after abnormal BNP level) 25.00 12.50 50.00 [14]
Costs (US $)
Echocardiogram (private sector) 103.04 51.52 154.56 [18]
Echocardiogram (public health system) 25.56 12.78 38.34 [19]
BNP level measurement 66.31 33.16 99.47 [18]
BNP, B-type natriuretic peptide.
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of events in these studies warrants larger margins for sensitivity
analyses. Therefore, we performed one-way sensitivity analysis
for all the model’s parameters, using half the original value for
the lower limit and double the original value for the upper limit.Results
Base Case
In the analysis from the private sector’s perspective, the first
strategy, based on annual echocardiography, generated mean
costs per patient of US $103.20 per year, resulting in a final cost
of US $30,951.53 per diagnosis of cardiotoxicity, as compared with
not performing any screening. The second strategy, based on
annual BNP level measurement, followed by echocardiography
only in patients with an abnormal result, generated mean costs
per patient of US $66.42 per year, resulting in a final cost of US
$19,925.64 per diagnosis of cardiotoxicity versus no screening,
and making it the dominant strategy.
In the analysis from PHS’s perspective, the strategy based on
annual BNP level measurement (assuming costs of BNP level
measurement in the PHS to be equal to those in the private
sector) resulted in mean costs per patient of US $67.44 per year
and a final cost of US $20,232.87 per diagnosis of cardiotoxicity. In
this perspective, the strategy based on annual echocardiography
was dominant, with mean costs per patient of US $25.56 and final
costs of US $7,668.00 per diagnosis of cardiotoxicity.
The main results are summarized in Table 2.
Sensitivity Analysis
When a higher frequency of cardiotoxicity was assumed (0.66%




Strategy 1—annual echocardiogram 103.20
Strategy 2—annual BNP level measurement,
echocardiogram if test result abnormal
74.04
Public health system’s perspective
Strategy 1—annual echocardiogram 25.56
Strategy 2—annual BNP level measurement,
echocardiogram if test result abnormal
67.44
BNP, B-type natriuretic peptide.
* Annual rate of detected cardiotoxicity.sector’s perspective fell to US $15,475.76 for the echocardiogram-
based strategy and US $9,962.82 for the BNP-based strategy. A
lower frequency (0.17%) raised the costs per diagnosis to US
$61,903.06 for the echocardiogram-based strategy and US
$29,851.28 for the BNP-based strategy.
As expected, costs of BNP level measurement and echocardio-
gram had a large influence on the results, keeping the dominance
with the strategy that uses the least costly screening test. In the
analysis from the PHS perspective, the BNP-based strategy
becomes dominant if the cost of BNP level measurement falls
below US$25.56.Discussion
Concerns have been raised regarding imatinib’s potential to
induce cardiotoxicity [12]. Although recent data suggest that this
is a rare complication [13–15], HF may seriously affect prognosis
in these patients [1]. In addition to increased long-lasting
morbidity and mortality, dose limitation and suboptimal usage
are important adverse effects.
Cardiac screening is usually recommended in patients taking
chemotherapy drugs more prone to induce cardiotoxicity, such
as anthracyclines. In the case of imatinib, however, the low
frequency of this adverse effect may not justify systematic
screening, because it can generate significant additional costs
with little potential benefit in the great majority of patients. The
clinical relevance of imatinib-induced HF and the real necessity
of monitoring all patients are questionable; consequently, an
economic analysis is extremely important to develop a recom-
mendation regarding cardiac screening.
This study has the merit of being the first economic analysis
to determine the cost-effectiveness of two different screening
strategies for patients receiving imatinib. In addition, it used datag).
l cost
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patients receiving imatinib. Its reliance on a relatively simple
model intends to keep most of the input parameters as reliable as
possible, minimizing assumptions.
Results of our cost-effectiveness analysis reflect the low
frequency of cardiotoxicity observed in the observational studies,
with both screening strategies obtaining similar effectiveness,
and dominance determined essentially by the costs of screening.
In the Brazilian private sector’s perspective, there is evidence
of superior cost-effectiveness of a screening strategy based
on BNP level measurements, reserving echocardiography for
patients with an abnormal test result. Even the BNP-based
strategy, however, would generate costs that approach US
$20,000 per diagnosis of cardiotoxicity. Currently, there is no
broadly accepted willingness-to-pay threshold for additional
costs per correct diagnosis. The World Health Organization–
recommended willingness-to-pay threshold of one to three times
the nation’s gross domestic product per capita is based on results
per quality-adjusted life-year; the logical conclusion would be
that cost-per-diagnosis results should be acceptable only at lower
thresholds than these. Currently, the Brazilian gross domestic
product per capita is US $10,800 [20]; the results for the BNP-
based strategy in the private sector are about two times higher
than that, and may be considered excessively high for systematic
adoption.
For the Brazilian PHS’s perspective, an assumption had to be
made regarding costs of BNP measurement, as it is not currently
reimbursed. Assuming the same costs found in the private sector,
the BNP-based strategy was dominated. It should be noted,
however, that in the Brazilian PHS, reimbursement values are
centrally defined by the government’s Ministry of Health. These
values are most often lower than values found in the private
sector, many times to the point of not covering actual health
spendings [22,23]. It is reasonable to assume that if BNP level
measurements become available for the PHS, the value of
reimbursement will likely be lower than the one encountered in
the private sector.
Therefore, the results of our analysis for the PHS should
probably not be used for final decisions regarding the relative
cost-effectiveness of screening strategies in the public sector, but
rather as an additional tool to be considered during the process of
defining a reimbursement value for BNP. This study has some
limitations. The study that supplies the input data had a low
frequency of the primary outcome, which may compromise its
power to predict the incidence of the outcome in other popula-
tions. Other studies, however, have confirmed that imatinib-
induced HF is an uncommon event [15,24–26].
Our model does not incorporate the potential benefit derived
from early diagnosis of cardiotoxicity, which may underestimate
the benefits of screening. It should be noted, however, that
objective data on the actual benefits of this early diagnosis are
scarce, and their addition would significantly increase the uncer-
tainty of the model.Conclusions
In the Brazilian private sector, systematic screening for cardio-
toxicity in patients using imatinib has a high cost per diagnosis.
If screening is to be adopted, a strategy based on BNP level
measurement, reserving echocardiography for patients with
abnormal test results, is preferred.
For the Brazilian PHS, the cost per diagnosis of cardiotoxicity
would be lower, due to the lower reimbursement values for
echocardiograms in this context. Selection of the best strategy
would depend on the reimbursement values adopted for BNP
level measurement, which is currently unavailable in the PHS.Source of financial support: The authors have no other
financial relationships to disclose.
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